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Objective. The randomized controlled trials (RCTs) on Guanxinning injection (GXN) in treating angina pectoris were published
only in Chinese and have not been systematically reviewed. This study aims to provide a PRISMA-compliant and internationally
accessible systematic review to evaluate the efficacy of GXN in treating angina pectoris. Methods. The RCTs were included
according to prespecified eligibility criteria. Meta-analysis was performed to evaluate the symptomatic (SYMPTOMS) and
electrocardiographic (ECG) improvements after treatment. Odds ratios (ORs) were used tomeasure effect sizes. Subgroup analysis,
sensitivity analysis, and metaregression were conducted to evaluate the robustness of the results. Results. Sixty-five RCTs published
between 2002 and 2012 with 6064 participants were included. Overall ORs comparing GXN with other drugs were 3.32 (95% CI:
[2.72, 4.04]) in SYMPTOMS and 2.59 (95% CI: [2.14, 3.15]) in ECG. Subgroup analysis, sensitivity analysis, and metaregression
found no statistically significant dependence of overall ORs upon specific study characteristics. Conclusion. This meta-analysis of
eligible RCTs provides evidence that GXN is effective in treating angina pectoris. This evidence warrants further RCTs of higher
quality, longer follow-up periods, larger sample sizes, andmulticentres/multicountries formore extensive subgroup, sensitivity, and
metaregression analyses.
1. Introduction
Ischemic heart disease (IHD) is a major cause of death and
global healthcare burden [1]. Angina pectoris, a symptom
of IHD, is a severe chest pain due to ischemia of the heart
muscle, during obstruction or spasm of the coronary arteries
[2]. In the United States, IHD accounts for 26.6% of all deaths
in 2005, with an age-adjusted male-to-female mortality ratio
of 1.5 [3]. The morbidity and mortality of angina in middle-
aged and elderly people were ranked the top among all
common diseases in China [4]. Three categories of conven-
tional Western medicine including nitrates (e.g., isosorbide
mononitrate), beta-receptor blockers (e.g., atenolol), and
calcium channel blockers (e.g., amlodipine) are commonly
used in treating angina [3].
Guanxinning injection (GXN, also known as Danshen
Chuanxiong Injection) comprises extracts from two well-
known traditional Chinese medicines Danshen (Salvia milti-
orrhiza) and Chuanxiong (Ligustrazine, Ligustium Wallichii
Franch) [5]. Danshen and its active compounds tanshi-
nones and isotanshinones have bioactivities against myocar-
dial ischemia, inflammation, and angiotensin-converting
enzyme [6]. Chuanxiong and its active compounds tetram-
ethylpyrazine and ferulic acid can dilate coronary arteries,
increase myocardial oxygen, and decrease platelet aggrega-
tion and thrombosis [7].
GXN was tested to be more effective than nitrates [8],
beta-receptor blockers [9], and calcium channel blockers [10]
in treating angina. Since the launch of GXN (2002) and prior
to this study, there has been only one systematic review,
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which is not compliant with PRISMA [11] and includes
only nine randomized controlled trials (RCTs) published
in Chinese between 2002 and 2010 [12]. The methods and
results of quality assessment of the included RCTs were not
clearly reported in the systematic review. Sensitivity and
subgroup analyses were missing. Hence, this study aims to
provide an internationally accessible, comprehensive, and
timely systematic review and meta-analysis in compliance
with PRISMA to assess the efficacy of GXN as amonotherapy
and combined therapywith conventionalWestern or Chinese
medicines in treating angina pectoris.
2. Methods
The procedures of this systematic review and meta-analysis
were conducted in accordance with the PRISMA guideline
[11], including the search and selection of studies, data extrac-
tion from the studies, and meta-analysis (overall, subgroup,
sensitivity, publication bias, and metaregression analysis).
2.1. Search Strategies. RCTs published on the efficacy of GXN
in treating angina pectoris were retrieved from major bibli-
ographical databases including Medline, PubMed, Cochrane
Library, ScienceDirect, Embase, China National Knowledge
Infrastructure (CNKI), WanFang Data, China Master Theses
Full-text Database (CMTD), and China Doctor Dissertations
Full-text Database (CDMD) between the inception dates of
databases and 2012 (last search on 18 March 2012). A simple
search strategy, that is, searching for the keywords “Guanx-
inning” or “danshen chuanxiong” or “danshenchuanxiong,”
was used to search all fields. For instance, the search in
WanFang Data using the keyword “Guanxinning” found 196
records and “danshen chuanxiong” found 17 records and
“danshenchuanxiong” found none. Exact search strategies
and query syntax for specific databases were customized
according to the same strategy.
2.2. Study Selection. Inclusion criteria for each study were (a)
the participants were suffering from and being treated for
angina pectoris; (b) the study was claimed as an RCT; (c)
the study compared the efficacy of GXN with conventional
(Western and Chinese medicine) drugs. Exclusion criteria
were (a) the study was a duplicated or redundant publication
and (b) the study did not include symptomatic improvement
as a major outcome.
Two reviewers (Y. Jia and F. Pan) independently searched
the databases and selected studies according to the inclusion
and exclusion criteria. Disagreements between reviewers
were resolved by consensus after discussion. Figure 1 shows
a flow diagram of study selection.
2.3. Data Extraction. Two reviewers (Y. Jia and F. Pan)
independently extracted data items, including (a) years of
publication; (b) numbers of authors; (c) follow-up periods;
(d) baseline characteristics of participants between groups;
(e) sample sizes; (f) outcome measures; (g) dosages and
follow-up periods; (h) type of angina; (i) frequencies of
adverse events (AE); and (j) the type of angina.
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Figure 1: Process of searching and screening studies.
2.4. Quality Assessment of Included Studies. Two reviewers
(Y. Jia and F. Pan) independently assessed the quality of the
included studies according to the Jadad scale [13], its refined
version the 𝑀 scale [14], and the Cochrane Collaboration’s
tool for assessing risk of bias [15]. The Jadad scale focused
on three criteria including “randomization,” “blinding,” and
“dropouts” for assessing the quality of RCT. The 𝑀 scale
added two criteria “baseline comparison of participants”
and “adverse event report” on top of the Jadad scale. The
Cochrane Collaboration’s tool for assessing risk of bias
includes “random sequence generation,” “allocation conceal-
ment,” “blinding of participants and personnel,” “blinding of
outcome assessment (patient-reported outcomes),” “blinding
of outcome assessment (SYMPTOMS),” “incomplete out-
come data addressed,” “reporting bias,” and “other sources of
bias.”
2.5. Criteria for Symptomatic and ECG Improvements. Effec-
tive symptomatic improvements should achieve at least 50%
(basic) or 80% (significant) reduction in frequency of feeling
angina chest pain [16]. Effective ECG improvements should
achieve (a) at least 0.05mV lowering at ST segment in
ECG (basic) or (b) nearly normal (significant) ECG dur-
ing an exercise test according to the International Society
and Federation of Cardiology/World Health Organization
[16].
2.6. Meta-Analysis. Effect sizes were represented by odds
ratios (ORs) [17] and their 95% confidence intervals (CI)
[18]. Overall meta-analysis and subgroup analysis employed
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the random-effects model for conservative generalizability.
Heterogeneity among studies was assessed by Chi-squared
(𝜒2) and I-squared (𝐼2) tests [19].
2.7. Subgroup and Sensitivity Analyses. Subgroup analysis was
conducted to evaluate the overall effects in the subgroups
according to years of publication (≤2008 or >2008), numbers
of authors (1 or >1), follow-up periods (≤14 days or >14 days),
sample sizes (<mean sample size or ≥mean sample size),
quality scores of the studies (<mean or ≥mean), different
type of angina, and different daily dosage of GXN. The
overall effects were also analyzed in subgroups of GXN for
monotherapy and adjunctive therapy. Sensitivity analysis was
carried out according to different criteria outcomes (basic or
significant) in SYMPTOMS and ECG and excluding studies
with maximum GXN dosage to assess their influence on the
overall effect sizes. The Mann-Whitney-Wilcoxon test was
used to compare two subgroups. The Kruskal-Wallis test and
the Bonferroni correction were used to compare multiple
subgroups. Kendall correlation between ORs of symptoms
and ECG was performed.
2.8. Metaregression and Risk of Bias across Studies. Funnel
plots [20], Begg’s test [21], and Egger’s test [22] were employed
to assess publication bias. Trim-and-fill method [23] was
conducted to identify and correct the funnel plot asymmetry
arising from publication bias. Metaregression [24] was con-
ducted to find the possible relationship between the overall
effects and the factors such as sample sizes, follow-up periods,
𝑀 scores, and years of publication.
2.9. Adverse Events. Information about adverse events (AEs)
of RCTs, including nonreported adverse events and types
and frequency of adverse events reported, was tabulated and
analyzed by basic statistics.
2.10. Statistical Analysis. All data analyses, including meta-
analysis, forest plot generation, funnel plot generation,
metaregression, Kendall correlation, Mann-Whitney-
Wilcoxon test, Kruskal-Wallis test, Begg’s test, and Egger’s
test, were performed using statistical software R [25] and its
“metafor” package for meta-analysis. 𝑃 values lower than
0.05 were considered statistically significant.
3. Results
3.1. Study Selection. Figure 1 depicts the process of study
selection. The search of bibliographical databases found 401
records, including 196 records from WanFang Data, 162
records from CNKI, 19 records from CMTD, 11 records
from ScienceDirect, 6 records from Medline, 5 records
from PubMed, and 2 records from CDMD. According to
prespecified selection criteria as described in Methods, 65
studies [26–90] were included for further quality assessment
and meta-analysis.
3.2. Study Characteristics. Table 1 lists the main character-
istics of the included studies. All included studies were
published in the Chinese language between 2004 and 2011
with a total of 6064 participants. The mean sample size was
93.3 (median: 88.0; 95% CI: [56.5, 130.1]). The follow-up
periods were between 1 and 30 days. GXNwas comparedwith
the conventional treatments in the included RCTs. Drugs
in control group mainly included nitrates, beta-receptor
blockers, calcium channel blockers, angiotensin-converting
enzyme inhibitors, and some conventional Chinese medici-
nal products for treating heart disease. Fifty-nine out of 65
RCTs employed GXN plus the conventional treatments in
the treatment group while the conventional treatments were
employed in control group. Dosage details were listed in Sup-
plementary Table 1 in the Supplementary Material available
online at http://dx.doi.org/10.1155/2013/282707. For outcome
measures, all 65 included studies reported symptomatic
(SYMPTOMS) changes while 38 studies also reported ECG
changes.
3.3. Quality Assessment of Included Studies. Table 2 shows the
results of quality assessment according to the Jadad scales,𝑀
scales, and the Cochrane Collaboration’s tool. According to
the Jadad scale (with a possible range between 0 and 5 points),
63 studies of all included studies scored 2 with two items
“randomization” and “dropouts,” one study [34] scored 3, and
one study [47] scored 4. According to the𝑀 scale, six studies
scored 2, three studies scored 2.5, 30 studies scored 3, 24
studies scored 4, and 2 studies scored 5. Fifty included studies
reported baseline comparison of participants in experiment
and control groups.Thirty-one studies did not report adverse
events.Three studies reported types of adverse events.Thirty-
one studies reported types and numbers of adverse events.
The assessment results of the Cochrane Collaboration’s tool
showed (1) low risk of bias in random sequence generation
for selection bias, blinding of outcome assessment (SYMP-
TOMS) for detection bias, and incomplete outcome data
addressed for attrition bias, (2) high risk of bias in alloca-
tion concealment for selection bias, blinding of participants
and personnel for performance bias, blinding of outcome
assessment (patient-reported outcomes) for detection bias,
and reporting bias for selecting reporting, and (3) unclear risk
of bias in other sources of bias for other bias.
3.4. Overall Effects of Included Studies. As shown in Figure 2
and Table 3, the overall OR of SYMPTOMS was 3.32 (95%
CI: [2.72, 4.04], 𝑍 = 11.93, 𝑃 < 0.0001) with significant
heterogeneity (tau = 0.23, 𝐼2 = 37%, 𝑃 = 0.0030) among the
65 studies with SYMPTOMS outcome. Figure 3 and Table 4
show that the overallORof ECGwas 2.59 (95%CI: [2.14, 3.15],
𝑍 = 9.68, 𝑃 < 0.0001) with nonsignificant heterogeneity
(tau = 0.11, 𝐼2 = 32%,𝑃 = 0.0539) among the 38 studies with
ECG outcome. Both ORs (SYMPTOMS and ECG) indicated
that GXN was more effective than the drugs in control group
in treating angina pectoris. The Kendall correlation between
SYMPTOMS and ECG in ORs was statistically significant
(tau = 0.2644; 𝑃 = 0.0200).
3.5. Subgroup Analysis. ORs of the subgroups in both SYMP-
TOMS (Table 3) and ECG (Table 4) were compared based
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Table 1: Characteristics of the included studies.
Study
Number
of
authors
Trial date
report
Sample
size
Followup
(day)
Baseline
comparison AE
Outcomes
measure Treatment group dosage Angina
Chen 2009 1 1 100 15 1 0 SYM, ECG GXN 20mL/d + CG Angina
Chen et al.
2011 3 1 100 10 0 0 SYM GXN 20mL/d + CG Angina
Chen 2006 1 1 62 14 1 1 SYM, ECG GXN 20mL/d + CG Angina
Cheng and
Zang 2010 2 1 43 14 1 0 SYM GXN 30mL/d + CG Unstable
Cheng et
al. 2011 3 1 76 14 1 1 SYM, ECG GXN 30mL/d + CG Angina
Dong XP
2009 1 0 100 1 0 0.5 SYM GXN 20mL/d Angina
Fu and
Meng 2011 2 0 47 10 1 0 SYM, ECG GXN 20mL/d + CG Angina
Fu et al.
2010 4 1 56 14 1 0 SYM, ECG
GXN 200ml + CG + shenmaiyin
40ml Angina
Gao et al.
2005 3 1 60 14 1 1 SYM, ECG GXN 20mL/d Angina
Gong et al.
2009 3 1 85 14 1 1 SYM, ECG
GXN 20mL/d + xueshuantong
20ml Stable
He and
Meng 2007 1 1 49 15 1 0 SYM GXN 20mL/d + CG Unstable
He 2009 1 1 120 28 1 1 SYM, ECG GXN 30mL/d + atorvastatin 10mg Unstable
Hou and
Gao 2009 2 1 128 14 1 1 SYM, ECG GXN 20mL/d + CG Stable
Huang et
al. 2011 4 0 120 7 1 1 SYM
GXN 20mL/d + CG +
xueshuantong 400mg Angina
Jiang et al.
2010 3 1 116 10 1 0 SYM, ECG GXN 20mL/d + CG Unstable
Jiang 2009 1 1 68 20 1 1 SYM, ECG GXN 20mL/d Angina
Jiang et al.
2010 5 0 56 7 0 1 SYM GXN 30mL/d Angina
Kong 2009 1 0 100 14 1 1 SYM GXN 30mL/d + CG Unstable
Lan et al.
2006 3 1 64 14 1 1 SYM GXN 20mL/d Angina
Li and Jia
2011 2 1 200 14 1 0 SYM, ECG GXN 30mL/d + CG Angina
Li and Lei
2005 2 1 156 14 0 1 SYM, ECG GXN 20mL/d + CG Angina
Li et al.
2009 5 1 168 14 1 0 SYM GXN 20mL/d + CG Angina
Li and Ran
2009 2 1 160 10 1 1 SYM GXN 20mL/d + CG Angina
Li 2004 1 0 83 7 1 0 SYM, ECG GXN 20mL/d + CG Unstable
Liang and
Feng 2010 2 0 120 14 1 0 SYM, ECG GXN 20mL/d + CG Unstable
Liu 2004 1 1 104 10 1 1 SYM GXN 20mL/d + CG Unstable
Liu and Li
2007 2 1 88 12 0 1 SYM GXN 20mL/d + CG Unstable
Liu 2005 1 1 80 30 1 0 SYM, ECG GXN 20mL/d + CG Unstable
Liu 2011 1 1 152 28 1 0 SYM, ECG GXN 20mL/d + CG Angina
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Table 1: Continued.
Study
Number
of
authors
Trial date
report
Sample
size
Followup
(day)
Baseline
comparison AE
Outcomes
measure Treatment group dosage Angina
Lu et al.
2006 3 1 68 30 1 0 SYM GXN 30mL/d + CG Angina
Ma and
Peng 2008 2 1 120 14 1 0 SYM GXN 30mL/d + CG Unstable
Nie and
Chen 2007 2 1 60 14 1 0 SYM, ECG GXN 20mL/d + CG Angina
Qiao and
Wu 2004 2 0 81 28 1 1 SYM, ECG GXN 20mL/d + CG Stable
Song 2010 1 1 82 7 0 0.5 SYM GXN 20mL/d + CG + diltiazem90mg/d Unstable
Su 2009 1 1 90 15 0 1 SYM, ECG GXN 6mL/d + CG Angina
Sun 2010 1 1 90 14 1 0 SYM, ECG GXN 30mL/d + CG Unstable
Sun et al.
2006 5 1 98 15 0 0 SYM GXN 20mL/d + CG Angina
Tian and
Wu 2006 2 1 62 14 1 1 SYM GXN 30mL/d + CG Unstable
Wan and
Xu 2009 2 0 120 14 1 1 SYM, ECG GXN 30mL/d + CG Unstable
Wang 2007 1 1 100 14 1 1 SYM, ECG GXN 30mL/d + CG Angina
Wang 2011 1 1 85 14 1 1 SYM, ECG GXN 20mL/d + CG Unstable
Wang 2011 2 1 112 14 1 1 SYM, ECG GXN 20mL/d + CG Unstable
Wang and
Ji 2008 2 1 60 14 0 0 SYM, ECG GXN 20mL/d + CG Unstable
Wang and
Sun 2007 2 1 92 10 0 0 SYM GXN 20mL/d + CG Unstable
Wang 2005 2 1 60 15 1 0 SYM GXN 20mL/d + CG Unstable
Wang 2010 1 0 80 14 1 1 SYM, ECG GXN 20mL/d + CG Stable
Wang 2005 1 0 76 15 0 0 SYM GXN 20mL/d + CG + shenmai30mL/d + tongxinluo 9 pills/d Unstable
Wang 2005 1 1 60 14 1 1 SYM GXN 20mL/d + CG Unstable
Wang et al.
2011 4 1 60 14 1 1 SYM GXN 20mL/d + CG Unstable
Wu et al.
2008 3 0 108 14 1 0 SYM GXN 20mL/d + CG Angina
Wu et al.
2011 4 1 144 7 1 0 SYM
GXN 20mL/d + CG + shenmai
50mL/d Unstable
Xia 2011 1 1 90 14 1 0 SYM, ECG GXN 30mL/d + CG Unstable
Yang and
Ma 2008 2 1 90 14 1 0 SYM, ECG GXN 30mL/d + CG Unstable
Ye et al.
2008 3 0 76 15 0 1 SYM GXN 20mL/d + CG Unstable
Yu and
Wang
2009
2 1 75 15 1 0 SYM, ECG GXN 20mL/d + CG Angina
Yuan 2005 1 0 104 14 1 0 SYM, ECG GXN 20mL/d + CG Angina
Zhang
2005 1 1 60 14 1 0 SYM, ECG GXN 10mL/d Angina
Zhang
2010 1 1 240 15 1 1 SYM, ECG GXN 20mL/d + CG Unstable
Zhang
2004 1 1 102 14 1 1 SYM, ECG
GXN 10mL/d + CG + ginkgo leaf
injection 10mL/d Angina
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Table 1: Continued.
Study
Number
of
authors
Trial date
report
Sample
size
Followup
(day)
Baseline
comparison AE
Outcomes
measure Treatment group dosage Angina
Zhang
2004 1 1 42 7 0 1 SYM GXN 20mL/d + CG Angina
Zhao et al.
2010 6 1 100 14 1 1 SYM, ECG
GXN 10mL/d + CG +
xueshuangtong 120mg Unstable
Zhao and
An 2008 2 1 90 28 1 1 SYM, ECG
GXN 20mL/d + CG + simvastatin
10–20mg/d Unstable
Zhao 2010 1 1 86 14 1 0 SYM, ECG GXN 30mL/d + CG Angina
Zhong et
al. 2007 8 1 60 10 0 0 SYM GXN 20mL/d + CG Angina
Zhu 2005 1 1 80 15 0 0.5 SYM, ECG GXN 20mL/d + CG Unstable
GXN is Guanxinning injection; LMWH is low molecular weight heparin; and shenmai is Shenmai injection. CG is interventions of control group; SYM is
SYMPTOMS; ECG is electrocardiogram; and AE is adverse event.The column of “Trial date report” shows that study did (1) or did not (0) report the trial date.
The column of “Baseline comparison” shows that the study did (1) or did not (0) report the baseline comparison between the treatment and control groups.
on the study characteristics including 𝑀 scores (≤3 or >3),
sample sizes (<93 or ≥93), number of authors (1 or >1), years
of publication (before or after January 1, 2008), reports of trial
dates (yes or no), baseline comparison of participants (yes or
no), reports of adverse events (yes or no), follow-up periods
(≤14 days or >14 days), GXN daily dosages (<20mL, 20mL,
>20mL), different angina types, and different treatments
including GXNmonotherapy versus control treatment, GXN
+ control versus control, andGXNmixed treatment + control
versus control.Therewas no statistically significant difference
between ORs of these subgroups.
3.6. Sensitivity Analysis. When the improvement criteria
were raised to the significant level from the basic level, the
overall results remained effective (i.e., OR> 1) and statistically
significant. The OR of overall SYMPTOMS decreased from
3.32 to 1.75 (95% CI: [1.54, 1.98], 𝑍 = 8.65, 𝑃 < 0.0001).
The OR of overall ECG decreased from 2.59 to 1.84 (95%
CI: [1.59, 2.14], 𝑍 = 8.06, 𝑃 < 0.0001). There was a
statistically significant correlation between the changes in
ORs of SYMPTOMS and ECG outcomes (tau = 0.2971,
𝑃 = 0.0089). When study [33] with maximum GXN dosage
was excluded, there was no statistically significant difference
between ORs of groups in both SYMPTOMS and ECG data.
3.7. Metaregression. Table 5 shows the results of metare-
gression between logOR and study characteristics. There
seemed to be no statistically significant relationship between
GXN’s efficacy and study characteristics, except that follow-
up periods made a significant difference (𝑃 = 0.0093) on the
logOR with ECG data.
3.8. Risk of Bias Across Studies. Visual assessment of funnel
plots (Figure 4) found obvious asymmetry, indicating that
there were publication biases in the results of both SYMP-
TOMS and ECG. Egger’s test (SYMPTOMS: 𝑡 = 2.0555,
𝑃 = 0.0440; ECG: 𝑡 = 0.9358, 𝑃 = 0.3556) and Begg’s test
(SYMPTOMS: 𝑧 = 0.1898, 𝑃 = 0.0257; ECG: 𝑧 = 0.2571, 𝑃 =
0.0236) detected statistically significant publication biases.
Trim-and-fill method found that there were 24 missing
studies for SYMPTOMS and 13 missing studies for ECG on
the left side of the corresponding funnel plots.
3.9. Adverse Events. As shown in Table 6, themost frequently
reported adverse event of GXN was headache. All adverse
effects were minor or well tolerated as they did not cause
dropouts except in one study [31] where six participants
dropped out because of the adverse effects. Headache, epigas-
tria discomfort, and palpitation were noted as the top three
adverse effects of drugs in control group. Adverse effects of
GXN were less than those of control drugs in the number of
types, severity, and frequency.
4. Discussion
This study provides the first comprehensive, up-to-date, and
PRISMA-compliant systematic review on the efficacy of GXN
in treating angina pectoris. Among 65 included RCTs with
6064 participants, overall ORs of SYMPTOMS and ECG
were 3.32 (95% CI: [2.72, 4.04]) (𝑃 < 0.0001) and 2.59
(95% CI: [2.14, 3.15]) (𝑃 < 0.0001), respectively. Subgroup
analysis also found statistical significance in the differences
between GXN treatment group and control group in testing
GXN monotherapy and adjunctive therapy. These results
indicated that GXN treatment is effective in treating angina
pectoris.
The results of this meta-analysis were robust as shown
in subgroup analysis, sensitivity analysis, and metaregression
on various parameters including sample sizes, follow-up
periods, daily dosages of GXN, types of angina pectoris, and
the quality scores of RCTs. Although funnel plots, Begg’s
test, Egger’s test, and trim-and-fill method found publication
biases, the overall effects would still favor GXN treatment
after enough number of less favorable studies were published
to restore the symmetry of funnel plots.
The efficacy of GXN in bothmonotherapy and adjunctive
therapy of angina pectoris exemplifies potential uses of
chemical components of GXN as one of the herbal products
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Table 2: Quality assessment of included studies.
Study C1 C2 C3 C4 C5 C6 C7 C8 Comparable Random Blind Dropout AE Jadad M
Chen 2009 Low High High High Low Low High High 1 1 0 1 0 2 3
Chen et al. 2011 Low Unclear High High Low Low High High 0 1 0 1 0 2 2
Chen 2006 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Cheng and Zeng 2010Low High High High Low Low High High 1 1 0 1 0 2 3
Cheng et al. 2011 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Dong 2009 Low High High High Low Low Unclear High 0 1 0 1 0.5 2 2.5
Fu and Meng 2011 Low High High High Low Low High High 1 1 0 1 0 2 3
Fu et al. 2010 Low High High High Low Low High High 1 1 0 1 0 2 3
Gao et al. 2005 Low Low High High Low Low Low Low 1 1 1 1 1 3 5
Gong et al. 2009 Low High High High Low Low Low Low 1 1 0 1 1 2 4
He 2007 Low High High High Low Low High High 1 1 0 1 0 2 3
He 2009 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Hou and Gao 2009 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Huang et al. 2011 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Jiang et al. 2010 Low High High High Low Low High High 1 1 0 1 0 2 3
Jiang 2009 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Jiang et al. 2010 Low High High High Low Low Low Low 0 1 0 1 1 2 3
Kong 2009 Low High High High Low Low Unclear Low 1 1 0 1 1 2 4
Lan et al. 2006 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Li and Jia 2011 Low High High High Low Low High High 1 1 0 1 0 2 3
Li and Lei 2005 Low High High High Low Low Low Low 0 1 0 1 1 2 3
Li et al. 2009 Low Low Low Low Low Low High High 1 1 2 1 0 4 5
Li and Ran 2009 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Li 2004 Low High High High Low Low High Low 1 1 0 1 0 2 3
Liang and Feng 2010 Low High High High Low Low High High 1 1 0 1 0 2 3
Liu 2004 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Liu and Li 2007 Low High High High Low Low High High 0 1 0 1 1 2 3
Liu 2005 Low High High High Low Low High High 1 1 0 1 0 2 3
Liu 2011 Low High High High Low Low High High 1 1 0 1 0 2 3
Lu et al. 2006 Low High High High Low Low High High 1 1 0 1 0 2 3
Ma and Peng 2008 Low High High High Low Low Low Low 1 1 0 1 0 2 3
Nie and Chen 2007 Low High High High Low Low High High 1 1 0 1 0 2 3
Qiao and Wu 2004 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Song 2010 Low High High High Low Low Low Unclear 0 1 0 1 0.5 2 2.5
Su 2009 Low Unclear High High Low Low Low Low 0 1 0 1 1 2 3
Sun 2010 Low High High High Low Low High High 1 1 0 1 0 2 3
Sun et al. 2006 Low High High High Low Low High Unclear 0 1 0 1 0 2 2
Tian and Wu 2006 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Wan and Xu 2009 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Wang 2007 Low High High High Low Low Low High 1 1 0 1 1 2 4
Wang 2011 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Wang 2011 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Wang and Ji 2008 Low High High High Low Low High High 0 1 0 1 0 2 2
Wang and Sun 2007 Low High High High Low Low High Unclear 0 1 0 1 0 2 2
Wang 2005 Low High High High Low Low High High 1 1 0 1 0 2 3
Wang 2010 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Wang 2005 Low High High High Low Low High Unclear 0 1 0 1 0 2 2
Wang 2005 Low Low Unclear High Low Low Low Low 1 1 0 1 1 2 4
Wang et al. 2011 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Wu et al. 2008 Low High High High Low Low High Unclear 1 1 0 1 0 2 3
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Table 2: Continued.
Study C1 C2 C3 C4 C5 C6 C7 C8 Comparable Random Blind Dropout AE Jadad M
Wu et al. 2011 Low High High High Low Low High High 1 1 0 1 0 2 3
Xia 2011 Low Low Unclear High Low Low High Unclear 1 1 0 1 0 2 3
Yang and Ma 2008 Low Low Unclear High Low Low High High 1 1 0 1 0 2 3
Ye et al. 2008 Low High High High Low Low Low Low 0 1 0 1 1 2 3
Yu and Wang 2009 Low High High High Low Low High High 1 1 0 1 0 2 3
Yuan 2005 Low High High High Low Low High High 1 1 0 1 0 2 3
Zhang 2005 Low High High High Low Low High High 1 1 0 1 0 2 3
Zhang 2010 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Zhang 2004 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Zhang 2004 Low High High High Low Low Low High 0 1 0 1 1 2 3
Zhao et al. 2010 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Zhao and An 2008 Low High High High Low Low Low Low 1 1 0 1 1 2 4
Zhao 2010 Low High High High Low Low High Unclear 1 1 0 1 0 2 3
Zhong et al. 2007 Low High High High Low Low High High 0 1 0 1 0 2 2
Zhu 2005 Low High High High Low Low Unclear Unclear 0 1 0 1 0.5 2 2.5
C1 is random sequence generation for selection bias; C2 is allocation concealment for selection bias; C3 is blinding of participants and personnel for performance
bias; C4 is blinding of outcome assessment (patient-reported outcomes) for detection bias; C5 is blinding of outcome assessment (SYMPTOMS) for detection
bias; C6 is incomplete outcomedata addressed for attrition bias; C7 is reporting bias for selecting reporting; C8 is other sources of bias for other bias; Comparable
is participants in treat group and control group comparable; Random is study described as randomized; Blind is study described as blinding; Dropout is
withdrawals and dropouts of participants; AE is the adverse effects; Low is low risk of bias; High is high risk of bias; Unclear is unclear risk of bias.
Table 3: Subgroups and sensitivity analysis on SYMPTOMS outcomes.
Group Number ofRCTs
Number of
participants OR Wilcoxon test 95% CI Z P (eff) 𝐼
2
𝜒
2 P (het)
M score ≤3 40 3625 3.21 W = 546 2.36, 4.35 7.46 <0.0001 54% 0.50 <0.0001
>3 25 2439 3.51 P = 0.5395 2.78, 4.43 10.50 <0.0001 0% 0 0.9858
Sample size <93 39 2772 3.22 W = 445.5 2.59, 4.01 10.51 <0.0001 0% 0 0.6150
≥93 26 3292 3.37 P = 0.4140 2.39, 4.76 6.89 <0.0001 60% 0.47 <0.0001
Number of authors 1 27 2485 3.18 W = 1189 2.39, 4.24 7.92 <0.0001 28% 0.16 0.1253
>1 38 3579 3.40 P = 0.7558 2.60, 4.46 8.87 <0.0001 44% 0.30 0.0031
Publication year ≤2008 31 2495 3.80 W = 441.5 3.01, 4.81 11.19 <0.0001 1% 0.01 0.2929
>2008 34 3569 2.94 P = 0.2642 2.20, 3.93 7.32 <0.0001 48% 0.34 0.0016
Trial date report Reported 51 4793 3.19 W = 2112.5 2.57, 3.95 10.52 <0.0001 36% 0.21 0.0189
Not reported 14 1271 3.84 P = 1 2.33, 6.33 5.28 <0.0001 47% 0.40 0.0254
Baseline
comparison
Reported 50 4808 3.56 W = 2112.5 2.84, 4.45 11.10 <0.0001 40% 0.25 0.0057
Not reported 15 1256 2.53 P = 1 1.75, 3.68 4.89 <0.0001 14% 0.08 0.1545
Adverse
events
Reported 31 2947 3.20 W = 1006 2.58, 3.97 10.59 <0.0001 0% 0 0.4304
Not reported 34 3117 3.48 P = 0.4678 2.53, 4.78 7.68 <0.0001 51% 0.44 0.0003
Follow-up
period (day)
≤14 48 4461 3.38 W = 440 2.75, 4.16 11.51 <0.0001 28% 0.14 0.1321
>14 17 1603 3.05 P = 0.6382 1.81, 5.16 4.18 <0.0001 61% 0.71 0.0005
GXN daily 6–200mL 65 6064 3.32 W = 2059 2.72, 4.04 11.93 <0.0001 37% 0.23 0.0030
Dosage (mL) 6–30mL 64 6008 3.34 P = 0.9231 2.73, 4.07 11.83 <0.0001 38% 0.24 0.0025
GXN daily <20 4 352 3.42 𝜒2 = 0.4290 1.48, 7.91 2.88 0.0040 38% 0.28 0.1717
Dosage (mL) 20 45 4235 3.16 df = 2 2.45, 4.07 8.85 <0.0001 46% 0.33 0.0004
>20 16 1477 3.87 P = 0.8069 2.84, 5.29 8.51 <0.0001 0% 0 0.8315
Types of angina
Stable 4 374 3.42 𝜒2 = 0.9900 1.89, 6.21 4.05 <0.0001 0% 0 0.7151
Unstable 31 2892 3.07 df = 2 2.26, 4.16 7.18 <0.0001 47% 0.34 0.0013
Angina 30 2798 3.61 P = 0.6096 2.72, 4.81 8.81 <0.0001 32% 0.19 0.1179
Improvement >50% 65 6064 3.32 W = 02.5 2.72, 4.04 11.93 <0.0001 37% 0.23 0.0030
>80% 63 5856 1.75 P < 0.0001 1.54, 1.98 8.65 <0.0001 25% 0.06 0.0557
GXN 1 6 408 3.19 𝜒2 = 0.4891 1.86, 5.49 4.21 <0.0001 0% 0 0.8454
GXN + CG 2 49 4681 3.43 df = 2 2.81, 4.19 12.07 <0.0001 21% 0.11 0.1177
GXN + CG +
additional 3 10 975 3.07 P = 0.7830 1.47, 6.41 2.99 0.00228 72% 0.98 <0.0001
CI is confidence interval; Z and P (eff) are statistical terms for evaluating overall effect; 𝐼2, 𝜒2, and P (het) are statistical terms for assessing heterogeneity
among studies.
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Study Test Control Weight OR [95% Cl]Positive Negative Positive Negative
Chen 2009 48 2 41 9 1.10% 5.27 [1.08, 25.78]
Chen et al. 2011 48 2 42 8 1.10% 4.57 [0.92, 22.73]
Chen 2006 29 3 21 9 1.30% 4.14 [1.00, 17.18]
Cheng and Zang 2010 22 1 15 5 0.70% 7.33 [0.78, 69.24]
Cheng et al. 2011 34 4 27 12 1.60% 3.78 [1.09, 13.04]
Dong XP 2009 55 5 33 7 1.60% 2.33 [0.68, 7.95]
Fu and Meng 2011 24 1 20 2 0.60% 2.40 [0.20, 28.45]
Fu et al. 2010 28 2 19 7 1.00% 5.16 [0.97, 27.56]
Gao et al. 2005 27 3 23 7 1.30% 2.74 [0.63, 11.82]
Gong et al. 2009 37 5 34 9 1.70% 1.96 [0.60, 6.43]
He and Meng 2007 24 3 15 7 1.20% 3.73 [0.83, 16.71]
He 2009 54 6 37 23 2.10% 5.59 [2.08, 15.07]
Hou and Gao 2009 66 4 46 14 1.70% 5.02 [1.55, 16.23]
Huang et al. 2011 58 2 45 15 1.20% 9.67 [2.10, 44.46]
Jiang et al. 2010 55 3 48 10 1.40% 3.82 [0.99, 14.69]
Jiang 2009 32 6 20 10 1.70% 2.67 [0.84, 8.47]
Jiang et al. 2010 27 1 24 4 0.60% 4.50 [0.47, 43.09]
Kong 2009 44 6 35 15 1.90% 3.14 [1.10, 8.94]
Lan et al. 2006 28 6 19 11 1.70% 2.70 [0.85, 8.56]
Li and Jia 2011 95 5 67 33 2.10% 9.36 [3.47, 25.22]
Li and Lei 2005 72 10 58 16 2.40% 1.99 [0.84, 4.71]
Li et al. 2009 79 5 66 18 1.90% 4.31 [1.52, 12.23]
Li and Ran 2009 84 16 41 19 2.60% 2.43 [1.13, 5.22]
Li 2004 41 1 26 15 0.70% 23.65 [2.95, 189.91]
Liang and Feng 2010 53 7 34 26 2.20% 5.79 [2.26, 14.81]
Liu et al. 2004 47 5 40 12 1.80% 2.82 [0.92, 8.69]
Liu and Li 2007 44 4 30 10 1.60% 3.67 [1.05, 12.78]
Liu 2005 38 2 28 12 1.10% 8.14 [1.69, 39.32]
Liu 2011 59 13 74 6 2.00% 0.37 [0.13, 1.03]
Lu et al. 2006 32 2 24 10 1.10% 6.67 [1.34, 33.28]
Ma and Peng 2008 56 4 41 19 1.70% 6.49 [2.05, 20.51]
Nie and Chen 2007 26 4 19 11 1.50% 3.76 [1.04, 13.65]
Qiao and Wu 2004 42 4 25 10 1.60% 4.20 [1.19, 14.82]
Song 2010 32 9 28 13 2.10% 1.65 [0.61, 4.44]
Su 2009 44 3 40 3 1.10% 1.10 [0.21, 5.77]
Sun 2010 43 7 30 10 1.90% 2.05 [0.70, 5.98]
Sun et al. 2006 43 7 32 16 2.00% 3.07 [1.13, 8.34]
Tian and Wu 2006 28 4 20 10 1.50% 3.50 [0.96, 12.76]
Wan and Xu 2009 57 3 50 10 1.40% 3.80 [0.99, 14.58]
Wang 2007 47 3 43 7 1.30% 2.55 [0.62, 10.49]
Wang 2011 28 5 29 13 1.70% 2.51 [0.79, 7.97]
Wang 2011 49 7 35 21 2.10% 4.20 [1.61, 10.96]
Wang and Ji 2008 27 3 22 8 1.30% 3.27 [0.77, 13.83]
Wang and Sun 2007 42 4 33 13 1.60% 4.14 [1.23, 13.87]
Wang 2005 26 4 19 11 1.50% 3.76 [1.04, 13.65]
Wang 2010 35 5 27 13 1.70% 3.37 [1.07, 10.61]
Wang 2005 36 2 31 7 1.10% 4.06 [0.79, 21.02]
Wang 2005 25 5 18 12 1.60% 3.33 [1.00, 11.14]
Wang et al. 2011 26 4 21 9 1.50% 2.79 [0.75, 10.33]
Wu et al. 2008 48 6 26 28 2.00% 8.62 [3.16, 23.48]
Wu et al. 2011 52 20 65 7 2.20% 0.28 [0.11, 0.71]
Xia 2011 43 7 30 10 1.90% 2.05 [0.70, 5.98]
Yang and Ma 2008 43 7 30 10 1.90% 2.05 [0.70, 5.98]
Ye et al. 2008 27 10 37 2 1.10% 0.15 [0.03, 0.72]
Yu and Wang 2009 38 2 27 8 1.10% 5.63 [1.11, 28.62]
Yuan 2005 48 4 38 14 1.70% 4.42 [1.35, 14.53]
Zhang 2005 31 4 13 12 1.50% 7.15 [1.94, 26.35]
Zhang 2010 116 4 102 18 1.80% 5.12 [1.68, 15.62]
Zhang 2004 49 3 35 15 1.50% 7.00 [1.88, 26.03]
Zhao et al. 2010 44 6 39 11 1.90% 2.07 [0.70, 6.12]
Zhao and An 2008 44 2 28 16 1.20% 12.57 [2.68, 58.90]
Zhao 2010 40 3 33 10 1.40% 4.04 [1.03, 15.90]
Zhong et al. 2007 33 2 20 5 1.00% 4.12 [0.73, 23.30]
Zhu 2005 38 2 34 6 1.10% 3.35 [0.63, 17.74]
Overall 1224 148 976 344 100% 3.32 [2.72, 4.04]
Figure 2: Forest plot of outcome measure SYMPTOMS.
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Study Test Control Weight OR [95% Cl]Positive Negative Positive Negative
Chen 2009 47 3 32 18 1.80% 8.81 [2.40, 32.41]
Chen 2006 28 4 20 10 1.80% 3.50 [0.96, 12.76]
Cheng at al. 2011 33 5 26 12 2.10% 3.05 [0.95, 9.75]
Fu and Meng 2011 24 1 19 3 0.60% 3.79 [0.36, 39.41]
Fu et al. 2010 24 6 14 12 200% 3.43 [1.05, 11.17]
Gao 2005 20 10 12 18 2.40% 3.00 [1.05, 8.60]
Gong et al. 2009 32 10 27 16 2.80% 1.90 [0.74, 4.86]
He 2009 34 26 24 36 3.90% 1.96 [0.95, 4.06]
Hou and Gao 2009 61 7 41 19 2.80% 4.04 [1.56, 10.47]
Jiang et al. 2010 55 3 46 12 1.70% 4.78 [1.27, 17.98]
Jiang 2009 30 8 15 15 2.40% 3.75 [1.30, 10.81]
Li and Jia 2011 60 40 24 76 4.60% 4.75 [2.58, 8.73]
Li and Lei 2005 65 17 42 32 4.00% 2.91 [1.44, 5.89]
Li 2004 32 10 21 20 2.80% 3.05 [1.19, 7.78]
Liang and Feng 2010 55 5 32 28 2.40% 9.62 [3.38, 27.41]
Liu 2005 25 15 21 19 3.00% 1.51 [0.62, 3.68]
Liu 2011 51 21 68 12 3.50% 0.43 [0.19, 0.95]
Nie and chen 2007 24 6 18 12 2.10% 2.67 [0.84, 8.46]
Qiao and Wu 2004 42 4 25 10 1.80% 4.20 [1.19, 14.82]
Su 2009 43 4 40 3 1.30% 0.81 [0.17, 3.83]
Sun 2010 38 12 26 14 2.90% 1.71 [0.68, 4.27]
Wan and Xu 2009 57 3 49 11 1.70% 4.27 [1.13, 16.17]
Wang 2007 36 14 28 22 3.30% 2.02 [0.88, 4.64]
Wang 2011 39 4 30 12 1.90% 3.90 [1.14, 13.31]
Wang 2011 46 10 30 26 3.20% 3.99 [1.68, 9.44]
Wang and Ji 2008 22 8 20 10 2.20% 1.37 [0.45, 4.17]
Wang 2010 34 6 26 14 2.30% 3.05 [1.03, 9.02]
Xia 2011 38 12 26 14 2.90% 1.71 [0.68, 4.27]
Yang and Ma 2008 38 12 26 14 2.90% 1.71 [0.68, 4.27]
Yu Wang 2009 31 9 21 14 2.60% 2.30 [0.84, 6.27]
Yuan 2005 39 13 30 22 3.30% 2.20 [0.95, 5.07]
Zhang 2005 24 11 11 14 2.40% 2.78 [0.96, 8.05]
Zhang 2010 76 44 46 74 5.30% 2.78 [1.65, 4.69]
Zhang 2004 46 6 34 16 2.50% 3.61 [1.28, 10.18]
Zhao et al. 2010 36 14 34 16 3.20% 1.21 [0.51, 2.85]
Zhao and Au 2008 27 19 17 27 3.30% 2.26 [0.97, 5.25]
Zhao 2010 38 5 32 11 2.10% 2.61 [0.82, 8.31]
Zhu 2005 36 4 26 14 1.90% 4.85 [1.43, 16.42]
Overall 1244 346 905 603 100% 259 [2.14, 3.15]
Figure 3: Forest plot of outcome measure ECG.
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Figure 4: Funnel plots of (a) the included studies with SYMPTOMS data and (b) the included studies with ECG data.
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Table 4: Subgroups and sensitivity analysis on ECG outcomes.
Group Number ofRCTs
Number of
participants OR Wilcoxon test 95% CI Z P (eff) 𝐼
2
𝜒
2 P (het)
M score ≤3 21 1995 2.47 W = 149 1.79, 3.41 5.53 <0.0001 52% 0.28 0.0025
>3 17 1709 2.71 P = 0.3945 2.17, 3.39 8.77 <0.0001 0% 0 0.9136
Sample size <93 23 1734 2.42 W = 127 1.93, 3.02 7.72 <0.0001 0% 0 0.9776
≥93 15 1970 2.86 P = 0.1789 1.94, 4.21 5.33 <0.0001 67% 0.37 0.0002
Number of authors 1 19 1872 2.30 W = 140 1.72, 3.08 5.65 <0.0001 41% 0.16 0.0358
>1 19 1832 2.98 P = 0.2428 2.34, 3.80 8.81 <0.0001 13% 0.04 0.4435
Publication year ≤2008 15 1268 2.49 W = 200 1.94, 3.20 7.17 <0.0001 0% 0 0.9538
>2008 23 2436 2.68 P = 0.4200 1.99, 3.61 6.47 <0.0001 52% 0.26 0.0025
Trial date report Reported 31 3069 2.43 W = 57 1.97, 3.00 8.29 <0.0001 34% 0.12 0.0511Not reported 7 635 3.67 P = 0.0548 2.36, 5.70 5.79 <0.0001 8% 0.03 0.5363
Baseline
comparison
Reported 34 3318 2.64 W = 85 2.14, 3.24 9.20 <0.0001 35% 0.12 0.0513
Not reported 4 386 2.29 P = 0.4325 1.25, 4.19 2.68 0.0074 23% 0.09 0.2200
Adverse
events
Reported 19 1955 2.67 W = 192 2.16, 3.30 9.14 <0.0001 0% 0 0.8792
Not reported 19 1749 2.54 P = 0.7480 1.80, 3.59 5.28 <0.0001 54% 0.31 0.0020
Follow-up
period (day)
≤14 27 2528 2.83 W = 129 2.34, 3.42 10.67 <0.0001 2% 0 0.7120
>14 11 1176 2.21 P = 0.5407 1.37, 3.57 3.27 <0.0001 65% 0.39 0.0024
GXN daily 6–200mL 38 3704 2.59 W = 707.5 2.14, 3.15 9.68 <0.0001 32% 0.11 0.0539
dosage (mL) 6–30mL 37 3648 2.58 P = 0.9662 2.12, 3.14 9.45 <0.0001 33% 0.1175 0.0448
GXN daily <20 4 352 1.89 𝜒2 = 3.4288, 1.00, 3.55 1.96 0.0497 27% 0.1148 0.2425
dosage (mL) 20 24 2324 2.80 df = 2 2.14, 3.66 7.51 <0.0001 43% 0.1820 0.0246
>20 10 1028 2.53 P = 0.1801 1.85, 3.46 5.81 <0.0001 14% 0.0365 0.5413
Types of angina
Stable 4 374 3.03 𝜒2 = 0.7010 1.80, 5.09 4.18 <0.0001 0% 0 0.6688
Unstable 16 1676 2.48 df = 2 1.95, 3.15 7.42 <0.0001 10% 0.02 0.2332
Angina 18 1654 2.60 P = 0.7043 1.87, 3.61 5.68 <0.0001 46% 0.22 0.0191
Improvement >50% 38 3704 2.59 W = 1050 2.14, 3.15 9.68 <0.0001 32% 0.11 0.0539
>80% 38 3704 1.84 P < 0.0001 1.59, 2.14 8.06 <0.0001 0% 0 0.8367
GXN 1 3 188 3.15 𝜒2 = 1.6604 1.71, 5.81 3.68 0.0002 0% 0 0.9202
GXN + CG 2 29 2963 2.68 df = 2 2.10, 3.41 7.98 <0.0001 42% 0.17 0.0157
GXN + CG +
additional 3 6 553 2.09 P = 0.4360 1.45, 3.01 3.94 <0.0001 0% 0 0.6382
CI is confidence interval; Z and P (eff) are statistical terms for evaluating overall effect; 𝐼2, 𝜒2, and P (het) are statistical terms for assessing heterogeneity
among studies.
Table 5: Metaregression analysis of the relationship between outcomes and the study characteristics.
log OR Number of RCTs Number of participants Factor Coefficient z P
SYMPTOMS 65 6064
M score 0.0663 0.4378 0.6615
Sample size −0.0013 −0.4955 0.6203
Number of authors −0.0466 −0.6283 0.5298
Publication year −0.0838 −1.9158 0.0554
Trial date report −0.1931 −0.7634 0.4453
Baseline comparison 0.3299 1.3376 0.1810
Adverse events −0.0965 −0.4646 0.6422
Follow-up period 0.0116 0.6126 0.5401
ECG 38 3704
M score 0.1191 0.7160 0.4740
Sample size 0.0006 0.2938 0.7689
Number of authors −0.0100 −0.1071 0.9147
Publication year −0.0180 −0.4296 0.6675
Trial date report −0.4255 −1.5606 0.1186
Baseline comparison 0.1520 0.4458 0.6558
Adverse events 0.1066 0.5300 0.5961
Follow-up period −0.0423 −2.6000 0.0093
that have offered great potentials in developing multitarget
agents to treat complex diseases [91]. Experimental studies
also showed that the aqueous extracts from both Danshen
and Chuanxiong significantly reduced the myocardial infarct
size in rat myocardial ischemia/reperfusion injury [92]. As
seen from the clinical and experimental findings, GXN seems
to be a promising resource for identifying new therapeutic
agents or new drug targets [93] in treating angina pectoris.
Although subgroup analysis and sensitivity analysis did
not suggest any significant factors which would influence
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Table 6: Adverse events reported in the included studies.
Treatment group Control group
Number of AEs Number of studies Number of AEs Number of studies
Headache 10 4 9 3
Dizziness 1 1 1 1
Palpitation 4 2 7 3
Skin ecchymosis 8 2 6 1
Serum transaminase elevated 1 1 NR NR
Nausea 1 1 3 1
Epigastria discomfort 4 2 8 3
Abnormal liver function 1 1 NR NR
Skin allergy NR NR 1 1
General weakness NR NR 1 1
Cold sweat NR NR 5 1
Hypotension NR NR 1 1
Skin mucosal bleeding NR NR 1 1
No AEs 0 27 0 24
Total AEs reports 30 9 43 11
No AE report 0 28 0 29
NR: not reported; AEs: adverse events.
the efficacy of GXN, clinical heterogeneity may contribute to
heterogeneity of this meta-analysis.
The limitations of this study include small sample sizes
and short follow-up periods. The mean sample size was 93,
which was lower than 124 as required by an alpha of 0.05, the
proportions of 0.899 for GXN and 0.742 for control group,
and a power of 0.8 [94].The patients of angina pectoris would
need long-term treatment [95], but most available RCTs have
short follow-up periods.
Another major limitation of this systematic review is the
low quality of included studies although most of included
RCT reports achieved the average quality of Chinese RCTs
[96, 97], which is still inadequate. Almost all (63 out of 65)
studies scored 2 at the Jadad scale, which ranges between 0
and 5. One study [34] reported single blinding and another
study [47] reported double blinding. Twenty-four RCTs
scored 4 at the 𝑀 scale and 40 RCTs scored less than 4 at
the𝑀 scale. There is evidence of the Cochrane Library’s tool
to show high risks of bias with the aspects of selection bias,
performance bias, and detection bias. More than that, less
than but almost half of included RCTs (28/65) did not report
adverse events, one possible reason of which is high reporting
bias for selecting reporting. Safety of GXN intervention
cannot be assessed because of incomplete reporting data.
Despite the fact that subgroup analysis found no statistically
significant differences in ORs of SYMPTOMS and ECG
between the RCTs of low andmedium𝑀 scores, high-quality
RCTs would be necessary to further support the efficacy of
GXN-based medicines over conventional Western drugs in
treating angina pectoris.
Seventy-three out of 6064 participants had AE.Themain
AEs included headache (19), skin ecchymosis (14), epigastria
discomfort (12), and palpitation (11). Headache was the most
frequent AE in this paper. The AE mechanisms of GXN are
not clear and definite. The functions of dilated blood vessels
and coronary artery blood circulation activating are possible
reasons that lead to adverse events.
According to this meta-analysis, GXN seems to be
effective in treating angina pectoris. As GXN contains the
herbal extracts from Salvia miltiorrhiza and Ligustrazine,
hence DSS, PAC, PAL, CAA, and SAB as the main active
ingredients with potential effects on coronary heart dis-
ease, angina pectoris, and cardiovascular diseases [98] by
enhancing coronary blood flow, improving the myocardial
systolic functions, and protecting myocardial cells [99],
further clinical, herbal formulation and pharmacological
studies are warranted for further research and develop-
ment.
5. Conclusion
This meta-analysis of eligible RCTs provides evidence that
GXN is effective in treating angina pectoris. This evidence
warrants further RCTs of higher quality, longer follow-up
periods, larger sample sizes, andmulticentres/multicountries
for more extensive subgroup, sensitivity, and metaregression
analyses.
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